X4 Pharmaceuticals To Present Research Data At The 2022 European Hematology Association (EHA) Congress Supporting Mechanism And Market Potential For Mavorixafor [TheStreet.com]
X4 Pharmaceuticals, Inc. (XFOR)
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am
Check Earnings Report
Company Research
Source: TheStreet.com
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it will present research data supporting the mechanism and market potential of its lead drug candidate, mavorixafor, as part of three posters at the upcoming to be held in Vienna, Austria, June 9-17, 2022. Mavorixafor is an oral, small molecule, CXCR4 antagonist currently being evaluated across three clinical studies: a fully enrolled Phase 3 trial in adults and adolescents with WHIM (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) syndrome; a Phase 1b clinical trial in adults with chronic neutropenia; and a fully enrolled Phase 1b clinical trial in adults with Waldenström's macroglobulinemia (WM), a rare B-cell lymphoma. "We are excited to present new data supporting our ongoing efforts to further elucidate correlations between clinical presentation an
Show less
Read more
Impact Snapshot
Event Time:
XFOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XFOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XFOR alerts
High impacting X4 Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
XFOR
News
- X4 Pharmaceuticals: PDUFA Excitement Ahead [Seeking Alpha]Seeking Alpha
- X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns [Yahoo! Finance]Yahoo! Finance
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- X4 Pharmaceuticals to Participate in Upcoming April Investor ConferencesGlobeNewswire
- X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
XFOR
Earnings
- 3/21/24 - Beat
XFOR
Analyst Actions
- 3/22/24 - HC Wainwright
XFOR
Sec Filings
- 4/5/24 - Form 8-K
- 4/1/24 - Form 8-K
- 3/21/24 - Form 10-K
- XFOR's page on the SEC website